Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared an article by Fatima Cardoso on X:
“Simultaneous Nature Medicine publications of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL.
Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER.
Waiting for EFS data, which will most likely impact practice.”
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial.
Authors: Fatima Cardoso, et al.
